Bio-Techne (TECH)
Supplies protein reagents, analysis instruments, spatial assays, and diagnostic controls.
Something off on this page? Send us feedback.
Supplies reagents, assay consumables, and analytical instruments for protein analysis, spatial biology, molecular diagnostics, and clinical quality control to researchers, biopharma companies, and clinical laboratories. Consumables provide most revenue; Protein Sciences is the larger of two segments, and a planned acquisition by Merck KGaA remains pending.
Develops and manufactures life-science reagents, analytical instruments, and diagnostic products for academic researchers, biopharma companies, and clinical laboratories. Protein Sciences, the larger segment, pairs a mostly internally manufactured catalog of proteins, antibodies, small molecules, and immunoassays under R&D Systems, Tocris, and Novus with ProteinSimple platforms for automated western blotting and other protein-analysis workflows.
Diagnostics and Spatial Biology sells RNAscope in-situ hybridization assays, Lunaphore COMET spatial-profiling instruments, Asuragen carrier-screening and oncology kits, and controls and calibrators for clinical diagnostics. Exosome Diagnostics has been divested. Sales span North America, Europe, China, and distributor-served markets, while a broad consumables portfolio supports repeat laboratory workflows. Demand depends on academic and biopharma research, bioprocessing activity, and regulated diagnostic markets. An agreed acquisition by Merck KGaA remains subject to shareholder and regulatory approvals.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 13, 2026 | Wells Fargo | Downgrade | Target: $370 | Target: $73 |
| Jul 9, 2026 | RBC Capital | Downgrade | ||
| Jun 30, 2026 | Benchmark | Downgrade | ||
| Jun 30, 2026 | TD Cowen | Downgrade | ||
| Jun 29, 2026 | Cowen & Co. | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $264.7M · Total debt $289.1M · Total assets $2.59B · Shareholders' equity $2.11B
- Revenue
- $321.2M
- Operating income
- $74.3M
- Net income
- $54.6M
HistoryDividendAnnual yield
| Institutions | 113.00% | 176.92M shares | |
|---|---|---|---|
| 614 holders · as of Jun 30, 2026 | |||
| Insiders | 0.33% | 521.7K shares | |
| 15 holders · as of Aug 18, 2026 | |||
| Adds to | 113.33% | ||
156.57M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 113.33%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 8.96% | 14.03M | as of Jun 30, 2026 |
FMR LLCInstitution | 8.17% | 12.79M | as of Jun 30, 2026 |
Vanguard Capital Management LLCInstitution | 6.53% | 10.22M | as of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 4.69% | 7.34M | as of Jun 30, 2026 |
HBK Investments L PInstitution | 4.36% | 6.83M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 8, 2026 | Amy E. Herr | director | −6,636 | $48.28 |
| Feb 17, 2026 | Amy E. Herr | director | −1,976 | $59.11 |
- Thermo Fisher Scientific
Reagent-and-instrument giant at $43B revenue contesting every research segment.
- Danaher
Antibody, bioproduction, and protein-analysis platform contesting three pillars.
- 10x Genomics
Spatial biology pure-play — Xenium and Visium HD rival RNAscope and COMET.
- Bio-Rad Laboratories
Western blotting, antibodies, and digital PCR — protein biology research rival.
- Bruker
Spatial biology via CosMx, GeoMx (NanoString), and CellScape spatial proteomics.
- QIAGEN
Molecular diagnostics platform in sample prep, NGS, ctDNA, and oncology assays.
- Repligen
Protein A, chromatography, filtration, and process analytics rival in CGT tools.
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Bio-Techne | $44.89 | −38.13% | $11.35B | 62.5 | 35.0 | 9.3 | +1.3% |
| Thermo Fisher Scientific | $658.52 | −0.03% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Danaher | $221.09 | −0.01% | $151.67B | 38.3 | 25.0 | 6.0 | +5.5% |
| 10x Genomics | $80.98 | +0.35% | $10.04B | — | — | 16.3 | −12.7% |
| Bio-Rad Laboratories | $379.57 | −0.01% | $10.16B | 45.7 | 36.8 | 3.9 | −0.1% |
| Bruker | $39.90 | −34.83% | $9.37B | — | 27.0 | 2.7 | +5.2% |
| QIAGEN | $43.69 | 0.00% | $9.24B | 23.0 | 17.5 | 4.4 | +0.3% |
| Repligen | $186.75 | +0.03% | $10.20B | 247.5 | 82.7 | 13.0 | +11.9% |
| Median | 38.3 | 26.1 | 5.3 | +5.2% |